Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IKT Inhibikase Therapeutics, Inc.

交易中 05-20 09:39:48 EDT

1.62

+0.05

+3.18%

最高1.62	最低1.57	成交量3.07万
今开1.58	昨收1.57	日振幅3.18%
总市值2.14亿	流通市值1.00亿	总股本1.32亿
成交额4.91万	换手率0.05%	流通股本6,184万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IKT","market":"US","secType":"STK","nameCN":"Inhibikase Therapeutics, Inc.","latestPrice":1.62,"timestamp":1779284366296,"preClose":1.57,"halted":0,"volume":30672,"delay":0,"changeRate":0.03184713375796181,"floatShares":61839000,"shares":132000000,"eps":-0.428236,"marketStatus":"交易中","change":0.05,"latestTime":"05-20 09:39:48 EDT","open":1.58,"high":1.62,"low":1.57,"amount":49110.6537648,"amplitude":0.031847,"askPrice":1.62,"askSize":300,"bidPrice":1.61,"bidSize":436,"shortable":3,"etf":0,"ttmEps":-0.428236,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779307200000},"marketStatusCode":2,"adr":0,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":1.57,"preHourTrading":{"tag":"盘前","latestPrice":1.58,"preClose":1.57,"latestTime":"09:29 EDT","volume":2354,"amount":3752.6804172,"timestamp":1779283741004,"change":0.01,"changeRate":0.006369,"amplitude":0.076433},"postHourTrading":{"tag":"盘后","latestPrice":1.57,"preClose":1.57,"latestTime":"17:42 EDT","volume":4742,"amount":7435.844,"timestamp":1779226927216,"change":0,"changeRate":0,"amplitude":0.023185},"volumeRatio":1.169994},"requestUrl":"/m/hq/s/IKT/tweets","defaultTab":"tweets","newsList":[{"id":"1144261486","title":"Inhibikase Therapeutics公布2026年第一季度财务业绩并概述近期动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1144261486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144261486?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:02","pubTimestamp":1778616142,"startTime":"0","endTime":"0","summary":"生物制药公司Inhibikase Therapeutics, Inc.近日披露了其截至2026年第一季度的财务报告，同时重点回顾了公司近期的业务进展与关键活动。\n财务业绩与运营亮点的发布，旨在向投资者及市场展示公司在报告期内的经营状况与发展轨迹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167034621","title":"Inhibikase Therapeutics启动首例患者入组，开展Ikt-001治疗肺动脉高压的全球三期IMPROVE-PAH研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167034621","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167034621?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563277,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. (简称Inhibikase) 宣布，其针对肺动脉高压（PAH）的创新疗法Ikt-001，已在全球三期临床试验IMPROVE-PAH中完成首例患者入组。这一重要进展标志着该药物临床开发进入关键阶段，有望为肺动脉高压患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136854543","title":"BofA全球研究启动对Inhibikase Therapeutics的覆盖，给予买入评级，目标价6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136854543","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136854543?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:51","pubTimestamp":1769007094,"startTime":"0","endTime":"0","summary":"BofA全球研究近日宣布，正式启动对生物制药公司Inhibikase Therapeutics, Inc.的股票研究覆盖，并首次给予\"买入\"评级。该机构为Inhibikase Therapeutics设定了6美元的目标股价。\n此次覆盖启动表明，机构投资者对该公司的发展前景持乐观态度。\"买入\"评级通常意味着分析师预期该股票在未来一段时间内将有优于市场平均水平的表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594289326","title":"Inhibikase Therapeutics, Inc.盘中异动 大幅拉升5.97%报1.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594289326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594289326?lang=zh_cn&edition=full","pubTime":"2025-12-25 01:46","pubTimestamp":1766598388,"startTime":"0","endTime":"0","summary":"北京时间2025年12月25日01时46分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速上涨5.97%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122501462897a0a77d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122501462897a0a77d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","IKT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168011037","title":"Inhibikase Therapeutics：公司或不时提供并出售最多185百万美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1168011037","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168011037?lang=zh_cn&edition=full","pubTime":"2025-12-20 05:30","pubTimestamp":1766179810,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics：公司或不时提供并出售最多185百万美元的普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182354773","title":"Inhibikase Therapeutics 股价在盘前交易中上涨7.2%，因公司推进实验性肺动脉高压药物进入后期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1182354773","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182354773?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:26","pubTimestamp":1763720772,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics 股价在盘前交易中上涨7.2%，因公司推进实验性肺动脉高压药物进入后期研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518327836","title":"Inhibikase Therapeutics, Inc.股价拉升13.07% 市值跌214.62万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518327836?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:39","pubTimestamp":1741613989,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时39分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速上涨13.07%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213949a26a27d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213949a26a27d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948892","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.76%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948892?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:36","pubTimestamp":1741185387,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时36分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅上涨5.76%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223628a260c929&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223628a260c929&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IKT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637316","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大涨8.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637316?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:57","pubTimestamp":1741013868,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时57分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅上涨8.91%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257489637b382&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257489637b382&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514373398","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大涨7.69%报2.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373398","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514373398?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:59","pubTimestamp":1740754746,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时59分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅上涨7.69%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225906abe0f1bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225906abe0f1bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869846","title":"Inhibikase Therapeutics, Inc.盘中异动 大幅拉升6.47%报2.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514869846?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:26","pubTimestamp":1740594413,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时26分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速上涨6.47%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270226539893d64c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270226539893d64c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514201535","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大跌6.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514201535?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:45","pubTimestamp":1740494723,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时45分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅下跌6.85%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224523abdc81ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224523abdc81ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722779","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大跌9.09%报2.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513722779?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:35","pubTimestamp":1740407759,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时35分，Inhibikase Therapeutics, Inc.股票出现波动，股价急速跳水9.09%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223559a2521583&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223559a2521583&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513158722","title":"Inhibikase Therapeutics, Inc.盘中异动 快速跳水5.21%报3.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513158722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513158722?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:51","pubTimestamp":1740160312,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时51分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速下挫5.21%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015152988e0a95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015152988e0a95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512482759","title":"Inhibikase Therapeutics, Inc.盘中异动 急速拉升6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482759","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512482759?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:55","pubTimestamp":1739984121,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时55分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅上涨6.15%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200055229628e44c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200055229628e44c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512614891","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.53%报2.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512614891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512614891?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:28","pubTimestamp":1739892524,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时28分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速上涨5.53%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328449627a274&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328449627a274&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511613831","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.38%报2.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511613831?lang=zh_cn&edition=full","pubTime":"2025-02-15 01:36","pubTimestamp":1739554601,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日01时36分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅拉升5.38%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215013641abcf2e26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215013641abcf2e26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510376115","title":"HC Wainwright & Co.：下调Inhibikase Therapeutics(IKT.US)评级，由买入调整至中性评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510376115","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510376115?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:44","pubTimestamp":1739364291,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：下调Inhibikase Therapeutics(IKT.US)评级，由买入调整至中性评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12204448120549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510980638","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.11%报2.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510980638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510980638?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:40","pubTimestamp":1739209200,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时40分，Inhibikase Therapeutics, Inc.股票出现波动，股价急速上涨5.11%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021101400198809cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021101400198809cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509269427","title":"Inhibikase Therapeutics, Inc.盘中异动 临近午盘快速跳水5.10%报2.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509269427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509269427?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:41","pubTimestamp":1738946511,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时41分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速下挫5.10%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208004151abc6475f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208004151abc6475f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IKT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibikase.com","stockEarnings":[{"period":"1week","weight":-0.1823},{"period":"1month","weight":-0.1421},{"period":"3month","weight":-0.1278},{"period":"6month","weight":0.0261},{"period":"1year","weight":-0.1604},{"period":"ytd","weight":-0.2341}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibikase Therapeutics, Inc.于2010年6月3日作为特拉华州的一家公司注册成立。他们是一家临床阶段的制药公司，开发改变心肺疾病（即肺动脉高压）病程的疗法，其中涉及通过III型受体酪氨酸激酶（包括血小板衍生生长因子受体和一种称为“c-Kit”的干细胞因子受体）的异常信号传导。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.188996},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.015653},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.007517},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.118796},{"month":5,"riseRate":0.5,"avgChangeRate":0.012315},{"month":6,"riseRate":0,"avgChangeRate":-0.232697},{"month":7,"riseRate":0.4,"avgChangeRate":-0.074238},{"month":8,"riseRate":0.6,"avgChangeRate":0.020579},{"month":9,"riseRate":0,"avgChangeRate":-0.145977},{"month":10,"riseRate":0.4,"avgChangeRate":0.077339},{"month":11,"riseRate":0.8,"avgChangeRate":0.007082},{"month":12,"riseRate":0.6,"avgChangeRate":0.075508}],"exchange":"NASDAQ","name":"Inhibikase Therapeutics, Inc.","nameEN":"Inhibikase Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibikase Therapeutics, Inc.(IKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibikase Therapeutics, Inc.,IKT,Inhibikase Therapeutics, Inc.股票,Inhibikase Therapeutics, Inc.股票老虎,Inhibikase Therapeutics, Inc.股票老虎国际,Inhibikase Therapeutics, Inc.行情,Inhibikase Therapeutics, Inc.股票行情,Inhibikase Therapeutics, Inc.股价,Inhibikase Therapeutics, Inc.股市,Inhibikase Therapeutics, Inc.股票价格,Inhibikase Therapeutics, Inc.股票交易,Inhibikase Therapeutics, Inc.股票购买,Inhibikase Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibikase Therapeutics, Inc.(IKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}